AZN.L - AstraZeneca PLC

LSE - LSE Delayed Price. Currency in GBp
6,089.00
+76.00 (+1.26%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close6,013.00
Open6,023.00
Bid6,087.00 x 6100
Ask6,089.00 x 13000
Day's Range5,981.00 - 6,103.00
52 Week Range5,110.00 - 6,540.00
Volume1,576,212
Avg. Volume2,585,390
Market Cap79.873B
Beta (3Y Monthly)1.16
PE Ratio (TTM)32.05
EPS (TTM)190.00
Earnings DateJul 25, 2019
Forward Dividend & Yield2.15 (3.76%)
Ex-Dividend Date2019-02-28
1y Target Est78.83
  • Business Wire3 days ago

    Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative to Empower and Unite Heart Attack Survivors Nationwide

    AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite heart attack survivors nationwide and elevate the importance of daily heart health management. The tour will kick off with a stop in Tampa, Florida, on June 5th, connecting local survivors with Bob Harper to share stories of strength and resilience. Further, the Survivors Have Heart initiative will bring together cardiovascular patient advocacy organizations, healthcare providers, policymakers and other community leaders to celebrate survivorship and champion the importance of cardiovascular health as part of a long-term healthy lifestyle.

  • Despite Its High P/E Ratio, Is AstraZeneca PLC (LON:AZN) Still Undervalued?
    Simply Wall St.4 days ago

    Despite Its High P/E Ratio, Is AstraZeneca PLC (LON:AZN) Still Undervalued?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a...

  • Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
    MarketWatch5 days ago

    Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices

    The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.

  • Business Wire5 days ago

    FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma

    A new integrated analysis of Phase III data for FASENRA® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and experienced a sustained improvement in exacerbation rates, lung function, asthma control and health-related quality of life. The analysis, presented today at the American Thoracic Society (ATS) 2019 International Conference, provides long-term efficacy and safety data for FASENRA from the one-year Phase III SIROCCO and CALIMA exacerbation trials, the one-year Phase III BORA extension trial and the 28-week Phase III ZONDA OCS-sparing trial.

  • ACCESSWIRE9 days ago

    ProPhotonix Limited Announces PPIX Announces AGM Results and PDMR Shareholdings

    ProPhotonix Announces Results of AGM and Director / PDMR Shareholdings SALEM, NEW HAMPSHIRE / ACCESSWIRE / May 16, 2019 / ProPhotonix Limited (OTC: STKR and London Stock Exchange - AIM: PPIX), a high technology ...

  • Business Wire9 days ago

    AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting

    Data focused on breaking treatment boundaries, treating patients earlier in their disease, and raising the bar for better outcomes

  • 3 Top Diabetes Stocks to Watch in May
    Motley Fool10 days ago

    3 Top Diabetes Stocks to Watch in May

    These three diabetes stocks should be on your radar right now.

  • GuruFocus.com11 days ago

    AstraZeneca Needs New Breast Cancer Drug to be Blockbuster

    AstraZeneca (ZN) needs a blockbuster to justify its nearly $7 billion investment for a share of Japan-based Daiichi Sankyo's (TSE:4568) drug to treat a type of breast cancer. Warning! GuruFocus has detected 5 Warning Signs with AZN. The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with another drug combination.

  • AstraZeneca Gets an $8 Billion Punishment
    Bloomberg16 days ago

    AstraZeneca Gets an $8 Billion Punishment

    AstraZeneca Plc’s first-ever stock sale has been a painful experience. The British drugmaker was exploiting its strong share price to get its financial house in order. Right now, its free cash flow isn’t enough to cover the dividend without some help from disposals.

  • Business Wire17 days ago

    AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer

    AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing (sometimes referred to as molecular testing or mutation testing), which can help patients and their physician find the treatment options that are right for them. AstraZeneca is partnering with the world-renowned golf pro to launch the Test It Back campaign, focused on ensuring complete biomarker testing becomes standard of care at every late-stage lung cancer diagnosis. The Test It Back site includes a series of inspiring videos featuring Day and his mother, Dening, whose decision to get mutation testing of her Stage IV non-small cell lung cancer last year informed her treatment decisions.

  • Business Wire22 days ago

    Change Makers Across the Oncology Community Recognized at 2019 Cancer Community (C2) Awards

    The oncology community gathered together last night to celebrate the winners of the first Cancer Community (C2) Awards. The awards – a partnership between AstraZeneca and Scientific American Custom Media – includes nominations submitted by organizations from across the cancer ecosystem and participation from an esteemed panel of third-party judges. “There is so much progress happening in cancer care, but it takes a village to make real change,” expressed Olivier Nataf, Head of US Oncology, AstraZeneca.

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of AZN.L earnings conference call or presentation 26-Apr-19 11:00am GMT

    Q1 2019 AstraZeneca PLC Earnings Call

  • Benzinga23 days ago

    The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...

  • AstraZeneca’s Lynparza Gives a Strong Performance in Q1
    Market Realist23 days ago

    AstraZeneca’s Lynparza Gives a Strong Performance in Q1

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Lynparza’s first-quarter performance In the first quarter, AstraZeneca’s (AZN) Lynparza sales rose 99% YoY (year-over-year) to $237 million on a reported

  • Reuters23 days ago

    AstraZeneca ties up with France's Transgene to develop viral immunotherapies

    Viral immunotherapy represents a new way of treating cancer by using transgenes, or genes that are artificially introduced into the genome of another organism. "AstraZeneca will select the transgenes to be encoded within the virus and will be responsible for further in-vivo pre-clinical development and, subject to option exercise, clinical development and commercialisation of these novel oncolytic immunotherapies," Transgene said. AstraZeneca has been moving deeper into cancer therapy market through wide-ranging deals, including those for immunotherapy and targeted therapy.

  • AstraZeneca’s Imfinzi Maintains Strong Growth in Q1
    Market Realist24 days ago

    AstraZeneca’s Imfinzi Maintains Strong Growth in Q1

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Imfinzi’s first-quarter performanceIn the first quarter, AstraZeneca’s (AZN) Imfinzi saw sales of $295 million, mainly driven by its rapid uptake as an

  • AstraZeneca’s Tagrisso Sees the Fastest Growth in Q1
    Market Realist24 days ago

    AstraZeneca’s Tagrisso Sees the Fastest Growth in Q1

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Tagrisso’s first-quarter performanceIn the first quarter, AstraZeneca’s (AZN) Tagrisso sales rose 86% YoY (year-over-year) to $630 million on a reported basis

  • BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery
    TechCrunch24 days ago

    BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery

    BenevolentAI is an AI company where AI actually means something. Founded in 2013, it focuses on "accelerating the journey from data to medicines." To achieve that, it has raised a whopping $202 million to look at early drug discovery through to late-stage clinical development, and has a research facility in Cambridge, U.K. where there is plenty of AI talent to be had. Today it has inked a long-term collaboration with pharma giant AstraZeneca to use AI and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

  • AstraZeneca’s Expense Guidance for Fiscal 2019
    Market Realist24 days ago

    AstraZeneca’s Expense Guidance for Fiscal 2019

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Expense guidanceIn its first-quarter press release, AstraZeneca (AZN) guided for its fiscal 2019 core operating expenses rising YoY (year-over-year) by a low

  • An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Suggests It's 46% Undervalued
    Simply Wall St.24 days ago

    An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Suggests It's 46% Undervalued

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for AstraZeneca PLC (LON:AZN) reflect what it's really worth? Today, we will...

  • What AstraZeneca Expects for EPS in Fiscal 2019
    Market Realist25 days ago

    What AstraZeneca Expects for EPS in Fiscal 2019

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)EPS guidance In its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for core EPS of $3.50–$3.70 in fiscal 2019. The company expects its YoY

  • AstraZeneca Reiterates Its Fiscal 2019 Revenue Guidance
    Market Realist25 days ago

    AstraZeneca Reiterates Its Fiscal 2019 Revenue Guidance

    How AstraZeneca Is Looking after Its First-Quarter Results(Continued from Prior Part)Revenue guidanceIn its first-quarter press release, AstraZeneca (AZN) reiterated its guidance for high-single-digit percentage growth in its fiscal 2019 product

  • Reuters25 days ago

    Trump, Democratic leaders to meet on drug prices soon -White House

    U.S. President Donald Trump will meet with congressional Democratic leaders soon to discuss drug prices, the White House said on Tuesday following infrastructure talks with House Speaker Nancy Pelosi and Senate Democratic leader Chuck Schumer. The White House said in a statement that the three agreed to meet "in the near future" over the health issue and that Trump "feels there is a long way to go" to lower drug costs, without elaborating.

  • What Analysts Recommend for AstraZeneca after Its Q1 Results
    Market Realist25 days ago

    What Analysts Recommend for AstraZeneca after Its Q1 Results

    How AstraZeneca Is Looking after Its First-Quarter ResultsStock price movement On April 26, AstraZeneca (AZN) announced its first-quarter results. Its revenue rose 6% YoY (year-over-year) to $5.49 billion on a reported basis and 11% on a CER

  • Better Big Pharma Stock: AbbVie vs. AstraZeneca
    Motley Fool26 days ago

    Better Big Pharma Stock: AbbVie vs. AstraZeneca

    These A-list drugmakers must both contend with expiring patents, new drug uncertainties, and hungry competitors. But they're in different stages of their cyclical journeys.